FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and can be used for treatment of Crohn's disease, ulcerous colitis and type 1 diabetes mellitus. For this purpose applied is APL peptide or its analogues, obtained from a human heat shock protein with a size of 60 kDa (hps60) in order to obtain a pharmaceutical composition. Also claimed are the pharmaceutical composition and the application of a medication for induction of apoptosis of pathogenic clones of T-cells in patients with inflammatory intestinal disease or type 1 diabetes.
EFFECT: group of inventions possesses an immunomodulating action and makes it possible to regulate mechanisms of the peripheral tolerance in gastrointestinal tract.
10 cl, 6 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING APL TYPE PEPTIDE | 2018 |
|
RU2778402C2 |
| PEPTIDE FOR TREATING CYTOKINE STORM SYNDROME | 2021 |
|
RU2834279C1 |
| RECOMBINANT CHIMERIC PROTEIN ANTH1, NUCLEIC ACID ENCODING ITS AND THEIR USING | 2003 |
|
RU2322455C2 |
| EZRIN DERIVATIVES PEPTIDES AND PHARMACEUTICAL COMPOSITIONS BASED THEREON | 2016 |
|
RU2694906C2 |
| ISOLATED POLYPEPTIDE AND USING IT FOR TREATING MALIGNANT DISEASE AND STIMULATING IMMUNE SYSTEM, PHARMACEUTICAL COMPOSITION CONTAINING SUCH POLYPEPTIDE AND METHOD OF TREATING CANCER | 2008 |
|
RU2518236C2 |
| COP1 FOR TREATMENT OF INFLAMMATORY DISEASES OF INTESTINE | 2004 |
|
RU2339397C2 |
| KOBITOLIMOD FOR USE IN TREATMENT OF INFLAMMATORY BOWEL DISEASE | 2018 |
|
RU2766356C2 |
| DPP3-BINDING MOLECULE AIMED AT SPECIFIC DPP3 EPITOPES AND BINDING TO THEM AND ITS USE FOR PREVENTION OR TREATMENT OF DISEASES/ACUTE CONDITIONS, WHICH ARE RELATED TO OXIDATIVE STRESS | 2018 |
|
RU2787033C2 |
| HUMANISED ANTIBODIES SPECIFIC FOR HSP65-DERIVED PEPTIDE-6, METHODS AND USES THEREOF | 2010 |
|
RU2596925C2 |
| ANTIBODIES AND POLYPEPTIDES AGAINST CD127 | 2017 |
|
RU2769352C2 |
